Navigation Links
ImmunoCellular Therapeutics to Host Conference Call and Webcast to Discuss ICT-107 Program in Newly Diagnosed Glioblastoma on November 24, 2015
Date:11/23/2015

LOS ANGELES, Nov. 23, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to host a conference call and webcast at 4:30 pm ET on Tuesday, November 24, 2015 to discuss the ICT-107 program in patients with newly diagnosed glioblastoma, including recently reported updated phase 2 clinical trial results and the design of the phase 3 registrational program. The conference call and webcast will be hosted by Andrew Gengos, President and CEO.

 

LIVE CALL:

(877) 853-5636 (toll-free); international dial-in: (631) 291-4544; conference code 89218581WEBCAST:

Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event.

The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, is open for patient enrollment. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells.

Contact:

ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com

Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO

 

 


'/>"/>
SOURCE ImmunoCellular Therapeutics, Ltd.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015
2. ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial
3. ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma
4. ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results
5. ImmunoCellular Therapeutics Enters into Manufacturing Agreement with PCT LLC, a Caladrius Company, for US Production of ICT-107 for Phase 3 Registration Trial
6. ImmunoCellular Therapeutics Presentation Now Available for On-Demand Viewing
7. ImmunoCellular Therapeutics Establishes Manufacturing Agreement with PharmaCell B.V. for European Production of ICT-107 for Phase 3 Registration Trial
8. ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
9. ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th
10. ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015
11. ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... ... October 08, 2019 , ... Help.org, a trusted online ... Best Rehab Facilities in Boston, Massachusetts for 2019. The informational guide recognizes the top ... , According to recent studies , drug overdose is the leading cause of ...
(Date:10/8/2019)... , ... October 08, 2019 , ... ... in an advanced dental implant seminar to enhance his skill and knowledge of ... The Implant Dentistry Continuum™ is a four-part series of classes that combines in-depth ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... Villa Healthcare, ... contest asking why they chose to work at Villa and what their work means ... CEO Mark Berger and CFO Steve Nagel prepared the giant checks. Anticipation was ...
Breaking Medicine Technology:
(Date:10/10/2019)... ... 2019 , ... Santa Rosa Consulting, Inc. , a ... industry, has completed the first phase of a comprehensive strategic and technological initiative ... towards a fully integrated health information management system (iHIMS). , The first ...
(Date:10/8/2019)... ... October 08, 2019 , ... Safe Harvest soups in ... King Sooper, Fry’s, Roundy’s, Smiths and Dillons. , Safe Harvest reinvented classic soup ... “Ingredient purity and fresh taste is paramount for us,” says Bryan Boches, co-founder ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... a majority interest in Advanced Fertility Care (AFC), an advanced reproductive services (RE) ... to expand the availability of RE services to expectant families throughout Arizona and ...
(Date:10/8/2019)... Hartford, CT (PRWEB) , ... October 08, 2019 ... ... at JawFixers in West Hartford, CT, help patients with missing teeth restore their ... year, this team of oral surgeons relies on advanced i-CAT® 3D Cone Beam ...
(Date:10/8/2019)... ... October 08, 2019 , ... Over the past three decades, Buffalo ... in the sports restaurant category by providing a higher-quality product and experience than the ... as well as a "RAISE A MUG FOR THE CAUSE" campaign in support of ...
Breaking Medicine News(10 mins):